Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Tonix Pharmaceuticals Holding Corp’s stock clocked out at $20.17, down -24.37% from its previous closing price of $26.67. In other words, the price has decreased by -$24.37 from its previous closing price. On the day, 2.14 million shares were traded. TNXP stock price reached its highest trading level at $25.712 during the session, while it also had its lowest trading level at $19.44.
Ratios:
To gain a deeper understanding of TNXP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.04 and its Current Ratio is at 6.50. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 129791528 and an Enterprise Value of 39134548. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.86 while its Price-to-Book (P/B) ratio in mrq is 0.63. Its current Enterprise Value per Revenue stands at 3.877 whereas that against EBITDA is -0.527.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.19, which has changed by -0.96682566 over the last 52 weeks, in comparison to a change of 0.06429911 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $1100.80, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is 6.06%, while the 200-Day Moving Average is calculated to be -39.30%.
Shares Statistics:
It appears that TNXP traded 1.66M shares on average per day over the past three months and 2382180 shares per day over the past ten days. A total of 6.43M shares are outstanding, with a floating share count of 6.43M. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.48% stake in the company. Shares short for TNXP as of 1741910400 were 878522 with a Short Ratio of 0.53, compared to 1739491200 on 333835. Therefore, it implies a Short% of Shares Outstanding of 878522 and a Short% of Float of 13.65.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Tonix Pharmaceuticals Holding Corp (TNXP) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$2.68, with high estimates of -$2.68 and low estimates of -$2.68.
Analysts are recommending an EPS of between -$11.89 and -$11.89 for the fiscal current year, implying an average EPS of -$11.89. EPS for the following year is -$4.67, with 1.0 analysts recommending between -$4.67 and -$4.67.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $2.6M. It ranges from a high estimate of $2.6M to a low estimate of $2.6M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.48MFor the next quarter, 1 analysts are estimating revenue of $2.8M. There is a high estimate of $2.8M for the next quarter, whereas the lowest estimate is $2.8M.
A total of 1 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $11.1M, while the lowest revenue estimate was $11.1M, resulting in an average revenue estimate of $11.1M. In the same quarter a year ago, actual revenue was $10.09MBased on 2 analysts’ estimates, the company’s revenue will be $98.8M in the next fiscal year. The high estimate is $166.1M and the low estimate is $31.5M.
